IGF1R and cancer: This suggests that while IGF-1R can be a valid target in ATC cells because of its location, it may work better when combined with other therapeutic agents, such as BRAF or MEK inhibitors, to improve patient outcomes, as demonstrated with other types of cancer, such as melanoma [43].